Fig. 5
From: A pan-cancer study of class-3 semaphorins as therapeutic targets in cancer
SEMA3 gene expression in breast cancer. a Association of SEMA3 gene expression with breast cancer molecular subtypes (P < .0001) tested with ANOVA. b Association of SEMA3 gene expression with immune infiltrate subtypes in breast cancer tested with ANOVA (P < .0001). c Correlation matrixes between SEMA3 gene expression and RNAss, DNAss, stromal score, immune score, and Estimate Score. Spearman correlation tests were used for testing